Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

17994.1 PFLS-LS

Project title

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Short description (English)	Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Abstract (German)	More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.
Abstract (English)	More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.